Cross-comparison of the genome sequences from human, chimpanzee, Neanderthal and a Denisovan hominin identifies novel potentially compensated mutations.

The recent publication of the draft genome sequences of the Neanderthal and a ∼50,000-year-old archaic hominin from Denisova Cave in southern Siberia has ushered in a new age in molecular archaeology. We previously cross-compared the human, chimpanzee and Neanderthal genome sequences with respect to a set of disease-causing/disease-associated missense and regulatory mutations (Human Gene Mutation Database) and succeeded in identifying genetic variants which, although apparently pathogenic in humans, may represent a 'compensated' wild-type state in at least one of the other two species. Here, in an attempt to identify further 'potentially compensated mutations' (PCMs) of interest, we have compared our dataset of disease-causing/disease-associated mutations with their corresponding nucleotide positions in the Denisovan hominin, Neanderthal and chimpanzee genomes. Of the 15 human putatively disease-causing mutations that were found to be compensated in chimpanzee, Denisovan or Neanderthal, only a solitary F5 variant (Val1736Met) was specific to the Denisovan. In humans, this missense mutation is associated with activated protein C resistance and an increased risk of thromboembolism and recurrent miscarriage. It is unclear at this juncture whether this variant was indeed a PCM in the Denisovan or whether it could instead have been associated with disease in this ancient hominin.

Introduction

The recent publication of the draft sequence of the Neanderthal genome [1] ushered in a new age in molecular archaeology [2,3]. This achievement was followed closely by the publication of the draft genome sequence (1.9-fold coverage) of a ~50,000-year old archaic hominin from Denisova Cave in southern Siberia [4]. This hominin (a 'Denisovan') is thought to have been a member of a sister group of hominins to the Neanderthals with whom they lived sympatrically during the Upper Pleistocene [4-7]. Denisovans appear to be more closely related to Neanderthals than humans, having diverged from Neanderthals about 640,000 years ago and from extant Africans about 804,000 years ago [4].

Access to DNA sequence data from ancient hominins not only promises to revolutionise our knowledge of hominin relationships, but is also potentially informative in the context of exploring the molecular basis of human genetic disease [8,9]. We have previously cross-compared the human, chimpanzee and Neanderthal genome sequences with a set of disease-causing/disease-associated missense and regulatory mutations in order to identify genetic variants which, although apparently pathogenic in humans, may represent a 'compensated' wild-type state in at least one of the other two species ('potentially compensated mutations' [PCMs]) [10]. PCMs correspond to variants that may have been deleterious for a certain period of evolutionary time but which persisted long enough in a given population or species to have become positively selected upon the introduction of a 'compensatory' nucleotide change [8,11-14]. Such compensatory changes are thought to be localised in the same gene as the PCM [15]. Not only do PCMs represent excellent candidates for recent population-specific selection (with different alleles having exhibited differential functional importance in different environments), but they may also furnish us with new insights into the genetic basis of susceptibility to common diseases [8,14]. Here, in an attempt to identify further PCMs of interest, we have compared a dataset of human mutations of putative pathological significance with their corresponding nucleotide positions in the Neanderthal, Denisovan and chimpanzee genomes.

Methods

Human Gene Mutation Database (HGMD) dataset

A total of 46,060 disease-causing (DMs) or disease-associated mutations had been obtained from the HGMD [16]http://www.hgmd.org as of 13th May 2010. These data comprised 44,348 missense mutations from within the coding regions of 2,628 genes, and 1,712 single base-pair substitutions from within the regulatory regions (5' and 3' untranslated/flanking regions) of 807 genes. Some 42,595 of the mutations were disease-causing (41,960 missense and 635 regulatory), whereas 3,465 represented disease-associated or functional polymorphisms (2,388 missense and 1,077 regulatory) (Table 1). The latter were further ascribed to three distinct subcategories: (1) DPs, comprising variants reported to be in statistically significant (p < 0.05) association with a particular human disease state but lacking experimental evidence of functionality -- for example, from expression studies; (2) disease-associated polymorphisms with experimental evidence of functionality (DFPs) such as, for example, altered in vitro gene expression or protein function; (3) FPs that have been shown in vitro or in vivo to affect the structure, function or expression of the gene or gene product but for which no statistically significant disease association has yet been reported (see http://www.hgmd.cf.ac.uk/docs/poly.html for further information).

Table 1

Missense and regulatory mutations from the HGMD used in this study, categorised by mutation type and putative role in disease aetiology

Mutation/polymorphismtype	Type and putative role in diseaseaetiology
	DM	DP	DFP	FP	Total
Coding sequence	41,960	942	295	1,151	44,348
Regulatory	635	340	391	346	1,712
Total	42,595	1,282	686	1,497	46,060

DM, disease-causing mutation; DP, disease-associated polymorphism lacking functional evidence; DFP, disease-associated polymorphism with functional evidence; FP, polymorphism with functional evidence but lacking a reported disease association as yet.

Identification of PCMs

A total of 8,280,851 nucleotide positions at which the Denisovan genome differs from either the human (NCBI36/hg18) or chimpanzee genome were downloaded from the website of the Max Planck Institute for Evolutionary Anthropology http://bioinf.eva.mpg.de/download/DenisovaGenome/Denisova_Neandertal_catalog.tgz[1,4]. The human and the Denisovan hominin were found to exhibit the same nucleotide at 7,283,268 positions (87.95 per cent), so that the human-chimpanzee mismatches must have arisen before the divergence of modern humans and Denisovans (termed a 'derived' or 'D' state in the Denisovan). A total of 941,947 positions (11.38 per cent) displayed the same nucleotide in both Denisovan and chimpanzee, suggesting that the respective substitutions were human specific ('ancestral' or 'A' state in the Denisovan). The remaining 55,636 positions, which display different nucleotides in modern humans, Denisovans and chimpanzees, were termed 'undefined' ('N' state). Of the 8,280,851 Denisovan nucleotide positions investigated here, there were 5,205,736 positions at which the Neanderthal was found to differ from at least one of modern human, chimpanzee and Denisovan. From these 5,205,736 sites, we identified 197 sites for which the apparent wild-type nucleotide in Denisovan, Neanderthal or chimpanzee was logged in the HGMD as disease causing or disease associated in modern humans (Table 2). From the remaining 3,075,115 sites, we identified 117 sites for which the apparent wild-type nucleotide in the Denisovan or chimpanzee was logged in the HGMD as disease causing or disease associated in either the Denisovan or chimpanzee (Table 3).

Table 2

HGMD-derived mutations identified as PCMs in the Denisovan, Neanderthal and/or chimpanzee genomes

	Mutation type and basis of disease aetiology
Mutation/regulatory type	PCM state	DM	DP	FP	DFP	Total
Coding sequence	Human	5/5	38/43	11/11	17/18	71/77
	Neanderthal	0/0	1/1	0/0	0/0	1/1
	Denisovan	1/1	0/0	0/0	0/0	1/1
	Ancient	0/0	1/1	2/4	0/0	3/5
	Chimpanzee	4/4	7/8	2/4	0/0	13/16
	Denisovan and chimpanzee	3/3	4/5	0/0	0/0	7/8
	Neanderthal and chimpanzee	2/2	4/6	1/1	1/1	8/10
	Others	1/1	0/1	0/0	0/0	1/2
	Total	16/16	55/65	16/20	18/19	105/120
Regulatory	Human	0	23	10	13	46
	Neanderthal	0	0	2	1	3
	Denisovan	0	0	0	3	3
	Ancient	0	2	0	1	3
	Chimpanzee	0	5	5	4	14
	Denisovan and chimpanzee	0	4	1	1	6
	Neanderthal and chimpanzee	0	1	1	0	2
	Others	0	0	0	1	1
	Total	0	35	19	24	78

'Human': The Denisovan nucleotide, Neanderthal nucleotide and chimpanzee nucleotide were identical to a human DM/disease-associated mutation; 'Neanderthal': The Neanderthal nucleotide was identical to the human DM/disease-associated mutation, whereas both the chimpanzee nucleotide and the Denisovan nucleotide were identical to the human wild-type nucleotide; 'Denisovan': The Denisovan nucleotide was identical to the human DM/disease-associated mutation, whereas both the chimpanzee nucleotide and the Neanderthal nucleotide were identical to the human wild-type nucleotide; 'Ancient': Both the Denisovan nucleotide and the Neanderthal nucleotide were identical to the human DM/disease-associated P mutation, whereas the chimpanzee nucleotide was identical to the human wild-type nucleotide. 'Chimpanzee': The chimpanzee nucleotide was identical to the human DM/disease-associated mutation, whereas both the Neanderthal nucleotide and the Denisovan nucleotide were identical to the modern human wild-type nucleotide. 'Denisovan and chimpanzee': Both the Denisovan nucleotide and the chimpanzee nucleotide were identical to the human DM/disease-associated mutation, whereas the Neanderthal nucleotide was identical to the human wild-type nucleotide; 'Neanderthal and chimpanzee': Both the Neanderthal nucleotide and the chimpanzee nucleotide were identical to the human DM/disease-associated mutation, whereas the Denisovan nucleotide was identical to the human wild-type nucleotide. Under coding sequence, 'a/b' means that there were a total number of 'b' mutations, of which 'a' were non-synonymous mutations (there were some synonymous mutations within the coding sequence; eg CM068190, CM077900).

PCM, potentially compensated mutations; DM, disease-causing mutation; DP, disease-associated polymorphism with functional evidence; FP, polymorphism with functional evidence but lacking a reported disease association as yet; DFP, disease-associated polymorphism with functional evidence.

Table 3

HGMD-derived mutations identified as PCMs in the Denisovan genome and/or chimpanzee genome

	Mutation type and basis of diseaseaetiology
Mutation/regulatorytype	PCM state	DM	DP	FP	DFP	Total
Codingsequence	Ancestral	5/5	24/29	9/9	5/7	43/50
	Derived	4/4	7/7	4/5	4/4	19/20
	Denisovan	0/0	4/6	2/2	0/0	6/8
	Others	0/0	1/1	0/0	0/0	1/1
	Total	9/9	36/43	15/16	9/11	69/79
Regulatory	Ancestral	2	6	9	12	29
	Derived	1	2	1	2	6
	Denisovan	0	1	0	2	3
	Total	3	9	10	16	38

Ancestral: Both the Denisovan nucleotide and the chimpanzee nucleotide were identical to the human DM/disease-associated mutation; Derived: The chimpanzee nucleotide was identical to the human DM/disease-associated mutation, whereas the Denisovan nucleotide was identical to the human wild-type nucleotide; Denisovan: The Denisovan nucleotide was identical to the human DM/disease-associated mutation, whereas the chimpanzee nucleotide was identical to the human wild-type nucleotide. Under coding sequence, 'a/b' means there were a total number of 'b' mutations, of which 'a' were non- synonymous mutations.

PCM, potentially compensated mutations; DM, disease-causing mutation; DP, disease-associated polymorphism with functional evidence; FP, polymorphism with functional evidence but lacking a reported disease association as yet; DFP, disease-associated polymorphism with functional evidence.

Gene ontology (GO) enrichment analysis

A GO enrichment analysis of PCM-containing genes against a background of 2,688 human disease-causing genes was performed using the DAVID bioinformatics tool [17]. The statistical significance of a particular GO term was calculated using Fisher's exact test, which was then adjusted to allow for multiple testing by means of the Benjamini-Hochberg correction [18].

Calculation of Wright's fixation index (FST) values

The FST measures the proportion of genetic diversity in a subdivided population that is attributable to allele frequency differences between subpopulations. Pairwise FST values have also been used as a measure of genetic distance between populations. In this context, the allele frequencies of polymorphic ancestral PCMs in selected populations were obtained from HapMap http://hapmap.ncbi.nlm.nih.gov/ and pairwise FST values were estimated for each polymorphism using the small sample estimate proposed by Weir and Hill [19]. The significance of individual FST values was then assessed by reference to the empirical distribution of FST among all single nucleotide polymorphisms (SNPs) in HapMap.

Results and discussion

Identification of PCMs in the Denisovan, Neanderthal and/or chimpanzee genomes

A total of 44,348 missense mutations from 2,628 genes and 1,712 putative regulatory mutations from 807 genes, which have been recorded in the HGMD as being either causative of (or associated with) a human inherited disease state, were cross-compared with the corresponding nucleotide positions in the Neanderthal, Denisovan and chimpanzee genomes.

When the 197 PCMs covered by both the Denisovan and the Neanderthal sequences were considered, these included 129 of 143 PCMs identified in the Neanderthal genome (10/12 DMs, 65/73 DPs, 25/26 FPs, 29/32 DFPs), and 123 (62 per cent) PCMs for which the Denisovan, Neanderthal and chimpanzee wild-type nucleotides were identical to the human disease-causing/disease-associated mutant allele. Of the 117 PCMs covered only by the Denisovan sequence, there were 79 (67.5 per cent) for which both the Denisovan nucleotide and the chimpanzee nucleotide were identical to a human DM/disease-associated mutation. This may be indicative of either a bottleneck effect or selection during the evolution of the modern human lineage. Of the 197 PCMs, there was one mutation that was compensated only in the Neanderthal, one that was compensated only in the Denisovan, five that were compensated in both Neanderthal and Denisovan and 16 that were compensated only in the chimpanzee. There were also 18 mutations that differed between the Neanderthal and the Denisovan, which could imply that such mutations were identical-by-state (Tables 2 and 3).

Disease-causing PCMs

There were 16 human DMs that were found to be potentially compensated in the chimpanzee, Denisovan or Neanderthal (covered by both the Neanderthal and the Denisovan sequence) and 12 human DMs potentially compensated in the chimpanzee or Denisovan (covered only by the Denisovan sequence) (Table 4).

Table 4

Human DMs identified as PCMs

Category	HGMDAcc. No	Chr	Chrom.location	Strand	Disease	Gene	Mutation	HGVS (cDNA)nomenclature	HGVS(protein)nomenclature	Type
Covered byboth theNeanderthaland theDenisovansequencea	CM993347	Chr1	67633930	+	Atopy	IL12RB2	A > G:GAA	NM_001559.2:c.2159A > G	NP_001550.1:p.H720R	Chimpanzee
	CM042258	Chr1	94337039	-	Stargardt disease	ABCA4	T > G:GGT	NM_000350.2:c.667A > C	NP_000341.2:p.K223Q	Denisovanandchimpanzee
	CM070090	Chr1	167765599	-	Thrombosis?	F5	C > T:CTC	NM_000130.4:c.5290G > A	NP_000121.2:p.V1764M	Denisovan
	CM099258	Chr15	40468491	+	Musculardystrophy?	CAPN3	G > A:AAA	NM_000070.2:c.706G > A	NP_000061.1:p.A236T	Human
	CM085365*	Chr15	43185730	-	Hypothyroidism	DUOX2	T > C:CCC	NM_014080.4:c.2033A > G	NP_054799.4:p.H678R	Human
	CM984025*	Chr19	18047618	-	Mycobacterialinfection	IL12RB1	T > C:CCT	NM_005535.1:c.641A > G	NP_005526.1:p.Q214R	Denisovanandchimpanzee
	CM044918	Chr19	41022117	-	Congenitalnephroticsyndrome,Finnish type	NPHS1	C > G:GGG	NM_004646.1:c.2971G > C	NP_004637.1:p.V991L	Human
	CM064230	Chr19	43656115	+	Malignanthyperthermia	RYR1	A > G:GAA	NM_000540.2:c.4024A > G	NP_000531.2:p.S1342G	Chimpanzee
	CM961339*	Chr22	30836050	+	Glucose/galactosemalabsorption	SLC5A1	C > G:GGC	NM_000343.1:c.1845C > G	NP_000334.1:p.H615Q	Denisovanandchimpanzee
	CM980573	Chr5	149341414	+	Achondrogenesis1B	SLC26A2	A > T:TAT	NM_000112.3:c.2065A > T	NP_000103.2:p.T689S	Neanderthalandchimpanzee
	CM043093	Chr6	25958824	-	Glycogen storagedisease 1c?	SLC17A3	C > T:TCC	NM_006632.3:c.601G > A	NP_006623.2:p.G201R	Chimpanzee
	CM072814	Chr7	86894112	-	Intrahepaticcholestasis,familialprogressive?	ABCB4	T > C:CCC	NM_000443.3:c.1954A > G	NP_000434.1:p.R652G	Human
	CM050323	Chr7	107129530	+	Pendredsyndrome?	SLC26A4	T > G:GTG	NM_000441.1:c.1826T > G	NP_000432.1:p.V609G	Neanderthalandchimpanzee
	CM983990	Chr8	22032655	-	Alopeciauniversalis?	HR	T > C:CCC	NM_005144.3:c.3064A > G	NP_005135.2:p.T1022A	Human
	CM099178*	Chr8	118899878	-	Multipleosteochondromas	EXT1	C > T:TCC	NM_000127.2:c.1609G > A	NP_000118.2:p.V537I	Chimpanzee
	CM085353*	ChrX	149390017	+	Hypospadias	MAMLD1	T > C:CYC	NM_005491.2:c.1514T > C	NP_005482.2:p.V505A	Others
Coveredonly by theDenisovansequenceb	CM043273	Chr1	195670491	+	Retinitispigmentosa	CRB1	G > A:AG	NM_201253.1:c.2875G > A	NP_957705.1:p.G959S	Chimpanzee
	CM067436	Chr11	7020956	+	Spermatogenicfailure	NLRP14	G > A:AG	NM_176822.3:c.1123G > A	NP_789792.1:p.A375T	Chimpanzee
	CM043536	Chr11	47326617	-	Cardiomyopathy,hypertrophic?	MYBPC3	T > C:CT	NM_000256.3:c.706A > G	NP_000247.2:p.S236G	Chimpanzee
	CM082943	Chr11	118720796	-	Primaryangle-closureglaucoma?	MFRP	C > T:TT	NM_031433.1:c.770G > A	NP_113621.1:p.R257H	Ancestral
	CM091988	Chr12	32913201	-	Arrhythmogenicright ventricularcardiomyopathy	PKP2	A > G:GG	NM_004572.3:c.1097T > C	NP_004563.2:p.L366P	Ancestral
	CM044579	Chr13	51413355	-	Wilson disease?	ATP7B	A > G:GG	NM_000053.2:c.3419T > C	NP_000044.2:p.V1140A	Ancestral
	CM073339	Chr17	24310977	-	Febrile seizures?	SEZ6	T > C:CC	NM_178860.4:c.1636A > G	NP_849191.3:p.T546A	Ancestral
	CM101950	Chr2	98363138	+	Progressive conedystrophy?	CNGA3	C > T:TC	NM_001298.2:c.284C > T	NP_001289.1:p.P95L	Chimpanzee
	CM961335	Chr22	30817700	+	Glucose/galactosemalabsorption	SLC5A1	G > A:AA	NM_000343.1:c.1231G > A	NP_000334.1:p.A411T	Ancestral
	CR080762	Chr1	15645754	+	Pancreatitis,chronic?	CTRC	T > C:CC	rs75456156:T > C	NA	Ancestral
	CR080761	Chr1	15645757	+	Pancreatitis,chronic?	CTRC	A > G:GG	rs760937:A > G	NA	Ancestral
	CR962526	Chr8	41774321	-	Spherocytosis	ANK1	A > G:GA	rs77173848:A > G	NA	Chimpanzee

aMutation type: modern human wild-type > modern human mutation: chimpanzee nucleotide, Denisovan nucleotide, Neanderthal nucleotide (both Neanderthal and Denisovan sequence covered). Y denotes pyrimidine.

bModern human wild-type > modern human mutation: chimpanzee nucleotide, Denisovan nucleotide (only Denisovan sequence covered).

*Previously reported by Zhang et al.[10]

Of the human DMs that were potentially compensated in the chimpanzee, Denisovan or Neanderthal, only the putatively pathological F5 variant was specific to the Denisovan. In humans, this missense mutation, Val1736Met, is associated with activated protein C resistance and an increased risk of thromboembolism and recurrent miscarriage [20,21]. It is unclear at this juncture whether this variant was indeed a PCM in the Denisovan or whether it could instead have been associated with disease in this archaic hominin.

Even though Denisovans appear to be more closely related to Neanderthals than humans, the Neanderthal and Denisovan were discrepant with respect to certain PCMs (eg the SLC5A1 H615Q variant associated with glucose-galactose malabsorption). In this case, the Denisovan (and the chimpanzee) possessed the allele that was mutant in humans (G), whereas the Neanderthal possessed the allele (C) which was wild-type in humans. In this context, it may be pertinent to mention that SLC5A1 is located on chromosome 22q12.3 within a region of putative gene flow from Neanderthal to Eurasian [1].

Some of the PCMs listed in Table 4 may well have been misclassified by the original authors as disease-causing in human (especially those variants which have been allocated a '?' by the HGMD; see Table 4) when they were actually neutral polymorphisms; however, this is much less likely in the case of the 16 human disease-causing mutations that are covered by both the Neanderthal and Denisovan sequences. These mutant alleles would have had to have been maintained in both Neanderthal and Denisovan populations for ~640,000 years, when these two hominins last shared a common ancestor, and this would have been unlikely if such variants had been neutral polymorphisms.

Statistically enriched GO terms were identified for genes containing human DMs identified as PCMs (Table 4) against a background of known disease-causing genes (from the HGMD) and are shown in Table S1 (Table 6). Five significantly enriched GO terms were found; all relate to the plasma membrane.

Table S1

Significantly enriched GO terms (Benjamini-corrected p-value <0.05) for human genes containing DMs identified as PCMs (listed in Table 4) against a background of known disease-causing genes. No significantly enriched GO terms were found to relate to biological processes or molecular function

GO Term	Category	Description	Foldenrichment	p-Value	Genes
GO:0031224	Cellular component	Intrinsic tomembrane	2.12	4.29E-03	SLC5A1, DUOX2, CNGA3, ABCA4, SLC26A2, MFRP, ABCB4,IL12RB2, SLC26A4, IL12RB1, CRB1, SLC17A3, PKP2, NPHS1,RYR1, EXT1, SEZ6, ATP7B
GO:0016021	Cellular component	Integral to membrane	2.21	4.59E-03	SLC5A1, DUOX2, CNGA3, ABCA4, SLC26A2, MFRP, ABCB4,IL12RB2, SLC26A4, IL12RB1, CRB1, SLC17A3, PKP2, NPHS1,RYR1, EXT1, SEZ6, ATP7B
GO:0005886	Cellular component	Plasma membrane	2.17	5.49E-03	SLC5A1, DUOX2, ABCA4, SLC26A2, ABCB4, IL12RB2, SLC26A4,IL12RB1, ANK1, CRB1, SLC17A3, F5, PKP2, NPHS1, RYR1, SEZ6,ATP7B
GO:0031226	Cellular component	Intrinsic to plasmamembrane	3.02	3.92E-02	IL12RB2, IL12RB1, SLC17A3, SLC5A1, NPHS1, RYR1, ABCA4,SLC26A2, ATP7B, ABCB4
GO:0005887	Cellular component	Integral to plasmamembrane	3.11	3.93E-02	IL12RB2, IL12RB1, SLC17A3, SLC5A1, NPHS1, RYR1, ABCA4,SLC26A2, ATP7B, ABCB4

With respect to the DPs/FPs, 100 DPs, 39 FPs and 43 DFPs were covered by both the Neanderthal and Denisovan sequences (Table S2 (Table 7)), while 52 DPs, 26 FPs and 27 DFPs were covered by the Denisovan but not the Neanderthal sequence (Table S3 (Table 8)); these DPs/FPs may be relevant to human genetic disease.

Table S2

PCMs covered by both the Denisovan sequence and the Neanderthal sequence

HGMDAcc	Chr	Location	Strand	Tag	Disease	Gene	Mutation	AA seq	Type
CM031993	Chr1	9246497	+	DFP	Cortisone reductasedeficiency, partial	H6PD	G > A:AAA	Arg-Gln	Human
CM040788	Chr1	11828655	-	DP	Stroke, increasedrisk, association with	NPPA	A > G:GGG	Term-Arg	Human
CM100611	Chr1	12005513	+	DFP	Breast cancer,reduced risk,association with	MIIP	A > G:GGG	Lys-Glu	Human
CM980072	Chr1	21767322	+	DFP	Hypophosphatasia,association with	ALPL	T > C:CCC	Tyr-His	Human
CM056598	Chr1	31865112	+	DP	Polydipsia-hyponatraemia,association with	HCRTR1	A > G:GAA	Ile-Val	Chimpanzee
CM994122	Chr1	35033356	+	DFP	Atherosclerosis,association with	GJA4	C > T:TTT	Pro-Ser	Human
CM065514	Chr1	55410663	-	DP	Parkinson's disease,risk, association with	USP24	G > A:AAA	Thr-Ile	Human
CM073141	Chr1	67457975	+	DP	Psoriasis, increasedrisk, association with	IL23R	T > C:CCC	Leu-Pro	Human
CM993347	Chr1	67633930	+	DM	Atopy	IL12RB2	A > G:GAA	His-Arg	Chimpanzee
CM067986	Chr1	86873963	+	DP	Chloride channeldeficiency,association with	CLCA3P	C > G:GGG	Tyr-Term	Human
CM042258	Chr1	94337039	-	DM	Stargardt disease	ABCA4	T > G:GGT	Lys-Gln	Denisovaandchimpanzee
CM067656	Chr1	156491643	+	DP	Guillain-Barre 'syndrome, reducedrisk, associationwith?	CD1A	C > G:GGC	Cys-Trp	Denisovaandchimpanzee
CM070090	Chr1	167765599	-	DM	Thrombosis?	F5	C > T:CTC	Val-Met	Denisovan
CM099896	Chr1	173615346	-	DP	Schizophrenia,association with	TNR	C > T:TTT	Arg-Lys	Human
CM023569	Chr1	199313698	-	DP	Hypokalaemicperiodic paralysis,association with?	CACNA1S	G > A:GRA	Gly-Gly	Unsure
CM920010	Chr1	228912417	-	DP	Hypertension,association with	AGT	A > G:GGG	Met-Thr	Human
CM065155	Chr1	240108924	+	DP	Colorectal cancer,increased risk,association with	EXO1	G > A:AAA	Glu-Lys	Human
CM033447	Chr10	42926693	+	DP	Hirschsprungdisease, associationwith	RET	A > G:GGG	Ala-Ala	Human
CM068190	Chr10	54198272	-	FP	Increased serummannose-bindinglectin (MBL) level,association with?	MBL2	C > G:CGG	Leu-Leu	Ancient
CM033482	Chr10	64085190	+	DP	Uric acidnephrolithiasis,association with	znf365d	G > A:GGA	Ala-Thr	Neanderthal
CM067461	Chr10	81691702	-	DP	Lung cancer,susceptibility to,association with	SFTPD	T > C:CCC	Thr-Ala	Human
CM035804	Chr11	524242	-	DP	Bladder cancer,association with?	HRAS	A > G:GAG	His-His	Neanderthalandchimpanzee
CM025891	Chr11	74585230	+	FP	Decreased enzymeactivity, associationwith	SLCO2B1	C > T:TTT	Ser-Phe	Human
CM080415	Chr11	113308238	+	FP	Altered receptorfunction, associationwith	HTR3B	A > C:CCC	Tyr-Ser	Human
CM950862	Chr12	5473868	+	DP	Schizophrenia,severe, increasedrisk, association with	NTF3	G > A:AGG	Gly-Glu	Chimpanzee
CM093840	Chr12	6023795	-	DP	von Willebranddisease, quantitativetype, associationwith	VWF	T > C:CCC	Thr-Ala	Human
CM994637	Chr12	6327323	-	DFP	Hypertension,reduced risk,association with	SCNN1A	T > C:CCC	Thr-Ala	Human
CM003671	Chr12	14884706	-	FP	Dombrock bloodgroup variation	ART4	T > C:TCC	Asn-Asp	Ancient
CM077900	Chr12	70659129	+	FP	Increased mRNAexpression,association with?	TPH2	G > A:GAA	Pro-Pro	Ancient
CM085048	Chr12	78539038	-	DP	Schizophrenia infemales, associationwith	PAWR	A > C:CCC	Ile-Met	Human
CM033453	Chr12	107542027	-	DFP	Coronary heartdisease, decreasedrisk, in AfricanAmericans,association with	SELPLG	C > T:TTT	Met-Ile	Human
CM022034	Chr13	32526193	+	DP	Age-relatedphenotypes,association with	KL	G > C:CGG	Cys-Ser	Chimpanzee
CM033777	Chr14	24170122	-	DP	Apoptosis, unable toinduce, associationwith	GZMB	A > G:GGG	Tyr-His	Human
CM070246	Chr14	60993992	+	DFP	Cerebral infarction,association with	PRKCH	G > A:AAA	Val-Ile	Human
CM067476	Chr15	41511938	-	DP	Lung cancer,susceptibility to,association with	TP53BP1	T > G:GGG	Lys-Gln	Human
CM067475	Chr15	41555066	-	DP	Lung cancer,susceptibility to,association with	TP53BP1	G > C:CCC	Asp-Glu	Human
CM085365	Chr15	43185730	-	DM	Hypothyroidism	DUOX2	T > C:CCC	His-Arg	Human
CM054862	Chr15	46213776	+	DP	Increased skinpigmentation,association with	SLC24A5	A > G:GGG	Thr-Ala	Human
CM057869	Chr15	76704628	-	FP	Altered function,association with	CHRNB4	T > C:CTT	Met-Val	Chimpanzee
CM031698	Chr15	97295748	+	DP	Increased longevity,association with?	IGF1R	G > A:AGG	Glu-Glu	Chimpanzee
CM057585	Chr16	1442858	-	DP	Lower femoral neckbone mineral densityin women,association with	CLCN7	C > T:TCT	Val-Met	Neanderthalandchimpanzee
CM983400	Chr16	27263704	+	DFP	Asthma, atopic,association with	IL4R	A > G:GGG	Ile-Val	Human
CM067985	Chr16	87788983	+	DP	Cadherin deficiency,association with	CDH15	C > A:AAA	Tyr-Term	Human
CM057933	Chr17	4585312	-	DP	Atheroscleroticstenosis, increased,association with	CXCL16	G > A:AAG	Ala-Val	Denisovaandchimpanzee
CM077855	Chr17	7532893	+	DP	Breast cancer,oestrogen receptor(ER) negative,association with?	WRAP53	C > G:GGG	Arg-Gly	Human
CM087381	Chr17	7987497	-	FP	Increased sexhormone-bindingglobulin levels,association with	PER1	C > G:GGG	Ala-Pro	Human
CM067489	Chr17	16468520	-	DP	Lung cancer,susceptibility to,association with	ZNF624	C > A:AAA	Lys-Asn	Human
CM030773	Chr17	19753133	-	DP	Cardiac disease,susceptibility to,association with	AKAP10	T > C:CCC	Ile-Val	Human
CM067336	Chr17	19802050	-	DP	Lung cancer,susceptibility to,association with	AKAP10	C > T:TTT	Arg-His	Human
CM096315	Chr17	38498462	-	DFP	Cervical cancer,decreased risk,association with	BRCA1	G > A:AAA	Pro-Leu	Human
CM093418	Chr17	39581073	+	DP	Hip bone mineraldensity, associationwith?	C17orf53	A > C:CCC	Thr-Pro	Human
CM032397	Chr17	41432502	+	DP	Progressivesupranuclear palsy,association with	STH	A > G:GAA	Gln-Arg	Chimpanzee
CM064363	Chr17	45788957	+	DP	Organ involvementin pseudoxantnomaelasticum (PXE),association with	XYLT2	T > C:CCC	Tyr-Tyr	Human
CM092499	Chr17	76468818	+	FP	Altered splicing,association with?	KIAA1303	A > G:GAA	Gln-Gln	Chimpanzee
CM080431	Chr19	11091881	+	FP	Increased plasmalow-densitylipoproteincholesterol,association with	LDLR	T > C:CTT	Val-Val	Chimpanzee
CM984025	Chr19	18047618	-	DM	Mycobacterialinfection	IL12RB1	T > C:CCT	Gln-Arg	Denisovaandchimpanzee
CM044918	Chr19	41022117	-	DM	Congenital nephroticsyndrome, Finnishtype	NPHS1	C > G:GGG	Val-Leu	Human
CM073386	Chr19	50087554	+	DP	Alzheimer's disease,late-onset,association with?	TOMM40	T > C:CCC	Phe-Phe	Human
CM004814	Chr19	50546759	-	DFP	Basal cell carcinoma,reduced risk,association with	ERCC2	T > G:GGG	Lys-Gln	Human
CM096319	Chr2	11276571	-	DP	Chronic kidneydisease in individualswith lowtriglycerides,association with	ROCK2	G > T:TGT	Thr-Asn	Neanderthalandchimpanzee
CM052876	Chr2	49043425	-	DP	Menstrual cyclelength, associationwith	FSHR	C > T:TTT	Ser-Asn	Human
CM073086	Chr2	85634047	-	DP	Higher body massindex, associationwith	GGCX	C > T:TCC	Arg-Gln	Chimpanzee
CM087379	Chr2	100957736	+	FP	Higher testosteronelevels, associationwith	NPAS2	A > G:GGG	Thr-Ala	Human
CM004559	Chr2	227369287	-	DP	Diabetes, type 2,association with	IRS1	T > C:CCT	Ala-Ala	Denisovaandchimpanzee
CM085146	Chr2	227839413	+	DP	Chronic obstructivepulmonary disease,association with	COL4A3	A > G:GAA	His-Arg	Chimpanzee
CM014824	Chr20	4653718	+	DP	Creutzfeldt-Jakobdisease, associationwith	PRND	C > T:TCT	Thr-Met	Neanderthalandchimpanzee
CM064121	Chr20	44075813	+	DP	Leukaemia, risk,association with	MMP9	G > C:CCC	Arg-Pro	Human
CM035699	Chr21	14403236	-	FP	Plasma high-densitylipoprotein (HDL)cholesterol,association with	LIPI	G > T:TTT	Asp-Glu	Human
CM057711	Chr21	33536125	+	DP	Multiple sclerosis,susceptibility to,association with	IFNAR2	T > G:GGG	Phe-Val	Human
CM025479	Chr21	44534334	+	DP	Alopecia universalis,association with	AIRE	C > G:GGG	Ser-Arg	Human
CM057927	Chr22	21957369	+	DP	Bipolar disorder,association with?	BCR	A > G:GGG	Asn-Ser	Human
CM065332	Chr22	24489289	+	DP	Colorectal cancer,increased risk,association with	MYO18B	G > A:AAA	Gly-Glu	Human
CM961339	Chr22	30836050	+	DM	Glucose/galactosemalabsorption	-SLC5A1	C > G:GGC	His-Gln	Denisovaandchimpanzee
CM096696	Chr22	35792882	-	DP	Iron status anderythrocyte volume,association with	TMPRSS6	A > G:GGG	Val-Ala	Human
CM092918	Chr22	37827350	+	FP	Increasedantiretroviral activity,association with	APOBEC3H	G > C:CCC	Gly-Arg	Human
CM910052	Chr22	49410905	-	DP	Phenotype modifier,association with?	ARSA	G > C:CCC	Thr-Ser	Human
CM023348	Chr3	336508	+	DP	Schizophrenia,association with	CHL1	C > T:TTT	Leu-Phe	Human
CM096382	Chr3	46476217	-	DFP	Periodontitis,aggressive,association with	LTF	T > C:CCC	Lys-Arg	Human
CM066581	Chr3	126109714	-	DP	Ulcerative colitis,association with	MUC13	T > G:GGG	Arg-Ser	Human
CM941277	Chr3	172214994	-	DP	Diabetes, type 2,association with	SLC2A2	G > A:AAG	Thr-Ile	Denisovaandchimpanzee
CM065290	Chr3	187925712	+	DP	Nephropathy,reduced risk,association with	KNG1	T > C:CCC	Met-Thr	Human
CM025429	Chr4	2960297	+	FP	Increased enzymaticactivity, associationwith	GRK4	G > T:TTT	Arg-Leu	Human
CM094340	Chr4	38476105	-	DFP	Leprosy, associationwith	TLR1	T > C:CCC	Asn-Ser	Human
CM890003	Chr4	100458342	-	FP	Alcoholdehydrogenase betavariant	ADH1B	T > C:CCC	His-Arg	Human
CM092574	Chr4	123756413	-	DFP	Asthma, atopic,association with	IL21	G > A:AAA	Cys-Cys	Human
CM031390	Chr4	141708518	-	DP	Waist-to-hip ratio,association with	UCP1	C > T:TTT	Ala-Thr	Human
CM004732	Chr5	1464412	-	DP	Parkinson's disease,protection against,association with?	SLC6A3	T > C:CTC	Ser-Ser	Neanderthalandchimpanzee
CM094298	Chr5	96165006	-	DFP	Cervical carcinomasurvival, associationwith	ERAP1	C > G:GGG	Arg-Pro	Human
CM0910115	Chr5	131424377	+	DP	Graves disease,association with	IL3	C > T:TTT	Pro-Ser	Human
CM043093	Chr6	25958824	-	DM	Glycogen storagedisease 1c?	SLC17A3	C > T:TCC	Gly-Arg	Chimpanzee
CM074911	Chr6	39433056	-	DP	Coronary heartdisease, associationwith	KIF6	A > G:GGG	Trp-Arg	Human
CM020385	Chr6	74550153	+	FP	Gov platelet antigenvariation	CD109	A > C:CCC	Tyr-Ser	Human
CM993455	Chr6	132214061	+	DFP	Insulin resistance,association with	ENPP1	A > C:CCC	Lys-Gln	Human
CM060415	Chr6	150156438	+	FP	Reduced stability,association with	PCMT1	A > G:AGG	Ile-Val	Ancient
CM072043	Chr6	160462998	+	FP	Reduced metforminuptake, associationwith	SLC22A1	C > T:TCC	Ser-Phe	Chimpanzee
CM005460	Chr7	17345635	+	FP	Higher inducedcytochrome P-450(CYP) 1A1 activity,association with	AHR	G > A:AAA	Arg-Lys	Human
CM055287	Chr7	45899194	+	DP	Renal function indiabetes, associationwith	IGFBP1	A > G:GGA	Ile-Met	Denisovaandchimpanzee
CM072814	Chr7	86894112	-	DM	Intrahepaticcholestasis, familialprogressive?	ABCB4	T > C:CCC	Arg-Gly	Human
CM064968	Chr7	91468556	+	DP	Colorectal cancer,increased risk,association with	AKAP9	G > T:TTT	Met-Ile	Human
CM930596	Chr7	94775382	-	DFP	Longevity, associationwith	PON1	T > C:CCC	Gln-Arg	Human
CM050323	Chr7	107129530	+	DM	Pendred syndrome?	SLC26A4	T > G:GTG	Val-Gly	Neanderthalandchimpanzee
CM060083	Chr7	122422409	-	DP	Alcohol dependence,risk, association with	TAS2R16	A > C:CAA	Asn-Lys	Chimpanzee
CM031370	Chr7	141319073	-	DP	Phenylthiocarbamidetaste sensitivity,association with	TAS2R38	T > C:CCC	Ile-Val	Human
CM031368	Chr7	141319814	-	DP	Phenylthiocarbamidetaste sensitivity,association with	TAS2R38	C > G:GGG	Ala-Pro	Human
CM081694	Chr8	6466450	+	DP	Cranial volume,association with	MCPH1	C > T:TTT	Ala-Val	Human
CM024569	Chr8	18124476	+	FP	Increased enzymaticactivity, associationwith	NAT1	T > G:GTG	Ser-Ala	Neanderthalandchimpanzee
CM983990	Chr8	22032655	-	DM	Alopecia universalis?	HR	T > C:CCC	Thr-Ala	Human
CM057431	Chr8	27518398	-	DP	Preeclampsia &essentialhypertension,association with?	CLU	A > G:GGG	His-His	Human
CM950017	Chr8	37942955	-	DFP	Hyperinsulinaemia,association with	ADRB3	A > G:GGG	Trp-Arg	Human
CM099178	Chr8	118899878	-	DM	Multipleosteochondromas	EXT1	C > T:TCC	Val-Ile	Chimpanzee
CM081761	Chr8	143758933	+	DFP	Gastric cancer,diffuse-type,association with	PSCA	C > T:TTT	Thr-Met	Human
CM094855	Chr9	14712477	-	DP	Low bone mineraldensity, associationwith	CER1	G > C:CGC	Ala-Gly	Neanderthalandchimpanzee
CM940804	Chr9	34639442	+	DFP	Galactosaemia,Duarte variant	GALT	A > G:GAG	Asn-Asp	Neanderthalandchimpanzee
CM071685	Chr9	89511843	+	DP	Inactivation ofextracellularsignal-regulatedkinase (ERK)-inducedapoptosis,association with	DAPK1	A > G:AGG	Asn-Ser	Ancient
CM990005	Chr9	106626574	-	FP	Higher plasma HDLcholesterol,association with	ABCA1	T > C:CCC	Ile-Met	Human
CM0910114	ChrX	77414973	-	DP	Asthma, associationwith	CYSLTR1	G > A:AAA	Phe-Phe	Human
CM085353	ChrX	149390017	+	DM	Hypospadias	MAMLD1	T > C:CYC	Val-Ala	Unsure
CR043164	Chr1	43575707	+	DP	Platelet count,association with?	MPL	C > A:AAA		Human
CR060579	Chr1	111020443	-	DP	Low insulinsensitivity,association with	KCNA3	T > C:TCC		Ancient
CR057791	Chr1	111571946	+	FP	Increased promoteractivity, associationwith	CHI3L2	G > T:GGT		Neanderthal
CR031479	Chr1	170894121	+	DFP	Systemic lupuserythematosus (SLE),association with	FASLG	C > T:TTT		Human
CR025943	Chr1	228917021	-	DP	Increasedangiotensinogenlevels, associationwith?	AGT	G > A:AGG		Chimpanzee
CR102882	Chr10	64279946	-	DFP	SLE, association with	EGR2	C > T:TCC		Chimpanzee
CR102883	Chr10	64280724	-	DFP	SLE, association with	EGR2	T > C:CTT		Chimpanzee
CR072313	Chr10	94452862	+	DP	Diabetes, type 2,association with?	HHEX	C > T:TCC		Chimpanzee
CR942079	Chr10	104587142	-	DP	Polycystic ovaries,association with	CYP17A1	A > G:GGG		Human
CR012509	Chr11	34416293	+	DP	Hypertension,susceptibility to,association with	CAT	G > A:AGA		Neanderthalandchimpanzee
CR072303	Chr11	44212190	+	DP	Diabetes, type 2,reduced risk,association with?	EXT2	C > T:CTT		Ancient
CR035965	Chr11	45863406	+	DFP	Alzheimer's disease,association with	MAPK8IP1	A > G:GGG		Human
CR094845	Chr11	74539529	+	FP	Increased mRNAexpression,association with	SLCO2B1	G > A:AAA		Human
CR045957	Chr11	102101690	-	DFP	Preterm prematurerupture ofmembranes,association with?	MMP8	G > A:GGA		Neanderthal
CR025510	Chr11	102331749	-	FP	Increasedtranscriptionalactivity, associationwith	MMP13	C > T:TCC		Chimpanzee
CR031478	Chr12	10203556	-	DP	Alzheimer disease,reduced risk,association with	OLR1	G > A:AAG		Denisovaandchimpanzee
CR082031	Chr12	55796928	-	DP	Schistosomiasisinfection, associationwith	STAT6	C > T:TTT		Human
CR087739	Chr13	42046024	+	DFP	Bone mineral densityin osteoporosis,association with?	TNFSF11	C > T:CTC		Denisovan
CR080758	Chr13	45577313	-	FP	Increased promoteractivity, associationwith	CPB2	T > C:CTT		Chimpanzee
CR994765	Chr13	112807756	+	DFP	Reduced plasma F7levels, associationwith	F7	G > T:CTT		Unsure
CR066661	Chr15	49336891	-	DP	Alzheimer's diseasein apolipoprotein E4(APOE4) carriers,increased risk,association with	CYP19A1	G > A:AAA		Human
CR002154	Chr15	56511231	+	DP	Dyslipidaemia andinsulin resistance,association with	LIPC	G > A:AGG		Chimpanzee
CR993820	Chr15	72828970	+	DFP	Increased activity insmokers, associationwith	CYP1A2	C > A:AAA		Human
CR102187	Chr16	13921167	+	DFP	Bladder cancer,increased risk,association with	ERCC4	A > C:CAA		Chimpanzee
CR066332	Chr16	54244319	+	DFP	Attention-deficithyperactivitydisorder, associationwith	SLC6A2	A > T:ATA		Denisovan
CR000229	Chr16	55552737	+	DFP	Higher HDLcholesterol level,association with	CETP	C > A:AAA		Human
CR084012	Chr17	25549137	-	FP	Increased expression,association with	SLC6A4	A > C:CCC		Human
CR035881	Chr17	29706729	+	FP	Increased monocytechemoattractantprotein-4 (MCP-4)plasma levels,association with	CCL13	C > T:CCT		Neanderthal
CR003707	Chr17	31231893	-	DFP	Atopic dermatitis,association with	CCL5	C > T:TTT		Human
CR078280	Chr17	35323475	-	DP	Asthma, increasedrisk, associationwith?	GSDMB	C > T:TTC		Denisovaandchimpanzee
CR090198	Chr17	38531642	-	FP	Promoter activity,association with	BRCA1	T > C:CCC		Human
CR052976	Chr17	43163827	+	DP	Asthma,aspirin-induced,association with	TBX21	T > C:CCC		Human
CR084013	Chr17	43178034	+	DP	Genital herpessimplex virus-2(HSV-2) infection,association with?	TBX21	G > A:AAA		Human
CR051707	Chr19	7718733	-	DFP	Dengue disease,protection against,association with	CD209	A > G:GGG		Human
CR095376	Chr19	40464739	+	DP	Increased liver ironconcentration	HAMP	A > G:GGA		Denisovaandchimpanzee
CR050427	Chr19	46188969	+	FP	CYP2B6 expression,association with	CYP2B6	T > C:CCC		Human
CR051274	Chr19	54149750	+	DFP	Disease progression,chronic lymphocyticleukaemia,association with	BAX	G > A:GAG		Denisovan
CR010588	Chr19	60077416	+	DP	Immunoglobulin Anephropathy,association with	FCAR	T > C:CCC		Human
CR051277	Chr2	69468799	-	DP	Obesity, associationwith	GFPT1	C > T:TTT		Human
CR025220	Chr2	234330398	+	DFP	Hyperbilirubinaemia,association with	UGT1A1	T > G:GGG		Human
CR075263	Chr20	17370063	+	DP	Diabetes, type 2,association with	PCSK2	T > C:CCC		Human
CR077665	Chr20	44066518	+	FP	Increased expression,association with?	MMP9	C > T:TTT		Human
CR078166	Chr21	33619134	+	FP	Increased expression,association with	IFNAR1	T > C:CCT		Denisovaandchimpanzee
CR054260	Chr21	38590628	+	FP	Promoter activity,association with	KCNJ15	T > G:GTT		Chimpanzee
CR096274	Chr21	42492734	+	DFP	Coronary arterydisease, severity,association with	ABCG1	T > G:GGT		Denisovaandchimpanzee
CR032439	Chr3	12328198	+	DFP	Increased height/lipidmetabolism,association with	PPARG	C > G:GGG		Human
CR066664	Chr3	129680794	-	DP	Coronary arterydisease, associationwith	GATA2	G > A:AGG		Chimpanzee
CR014438	Chr3	185572960	-	DP	Myocardial infarction,association with	THPO	C > T:TTT		Human
CR004797	Chr4	26101320	-	DP	Higher percentagebody fat, associationwith	CCKAR	C > A:ACC		Chimpanzee
CR045948	Chr4	69995928	+	FP	Promoter activity,association with	UGT2B7	G > A:AAA		Human
CR025435	Chr4	111053559	+	DFP	Malignant melanoma,association with	EGF	A > G:GGG		Human
CR057903	Chr4	155703465	+	DFP	Cerebral infarction,association with	FGB	C > T:TTT		Human
CR071281	Chr4	156348632	+	DP	Obesity, associationwith	NPY2R	C > T:TTT		Human
CR071289	Chr5	1499389	-	DP	Attention-deficithyperactivitydisorder, associationwith	SLC6A3	A > G:GGG		Human
CR086597	Chr5	110434641	+	FP	Increased promoteractivity, associationwith	TSLP	C > T:TCC		Chimpanzee
CR035513	Chr5	131436741	+	DP	Reduced severity inatopic dermatitis,association with	CSF2	A > C:CCC		Human
CR015845	Chr5	132020708	+	DP	Asthma, associationwith	IL13	C > T:TTC		Denisovaandchimpanzee
CR082018	Chr6	78227843	-	DFP	Aggressive behaviour,association with	HTR1B	C > T:TCC		Chimpanzee
CR073540	Chr6	131935252	+	DP	Myocardial infarction,association with	ARG1	G > T:TTT		Human
CR052970	Chr6	132254387	+	DP	Obesity, associationwith	ENPP1	A > G:GGG		Human
CR075243	Chr6	132314950	-	DFP	Systemic sclerosis,association with	CTGF	C > G:CGG		Ancient
CR075274	Chr6	133077018	-	DP	HDL cholesterolconcentration,association with	VNN1	A > C:CCC		Human
CR077383	Chr6	154401054	+	FP	Increased promoteractivity, associationwith	OPRM1	A > G:GGG		Human
CR066667	Chr7	30969948	+	DP	Breast cancer,decreased risk,association with	GHRHR	C > T:TTT		Human
CR092300	Chr7	111902894	+	DFP	Severity in cysticfibrosis, associationwith	IFRD1	C > T:TTT		Human
CR068449	Chr7	128381961	+	DP	SLE, associationwith?	IRF5	C > T:TTT		Human
CR022507	Chr7	136351848	+	DP	Major depression inwomen, associationwith	CHRM2	T > A:AAA		Human
CR971950	Chr8	19840951	+	FP	Lower plasmatriglyceride level,association with	LPL	T > G:GGG		Human
CR023703	Chr8	120034205	-	DP	Decreased bonemineral density,association with?	TNFRSF11B	C > T:TTT		Human
CR084001	Chr9	70877744	+	DP	Myocardial infarction,association with	FXN	C > T:TTT		Human
CR102176	Chr9	100952292	+	DFP	Breast cancer,association with	TGFBR1	A > G:GGG		Human
CR020827	Chr9	106730271	-	DP	Increased risk ofcoronary arterydisease, associationwith	ABCA1	G > A:AAA		Human
CR045560	Chr9	106730659	-	FP	Reduced plasmaHDL cholesterol,association with	ABCA1	C > G:GGG		Human
CR091269	Chr9	116608587	-	DFP	Crohn's disease,susceptibility to,association with	TNFSF15	A > G:GGG		Human
CR034594	Chr9	124172343	+	FP	Inhibition ofprostaglandin H2formation,association with?	PTGS1	A > G:GAG		Neanderthalandchimpanzee
CR054255	Chr9	127043845	-	DP	Bipolar disorder,association with?	HSPA5	T > C:CCC		Human
CR077381	ChrX	113724838	+	FP	Reduced promoteractivity, associationwith	HTR2C	G > C:CGG		Chimpanzee
CR063398	ChrX	135554616	+	FP	Increased solubleCD40 ligand(CD40L) levels,association with	CD40LG	A > G:GGG		Human

Table S3

PCMs covered by the Denisovan sequence but not the Neanderthal sequence

Acc	Chr	Location	Strand	Tag	Disease	Gene	Mutation	AA seq	Type
CM062419	chr1	19483828	-	DP	Leukaemia, risk,association with	AKR7A3	C > T:CT	Asp-Asn	Denisovan
CM098300	chr1	24074507	-	DFP	Eating disorders,association with	CNR2	T > C:CC	Gln-Arg	Ancestral
CM066774	chr1	110267989	+	DP	Periodontitis,association with?	CSF1	T > C:CC	Leu-Pro	Ancestral
CM094244	chr1	111656412	+	FP	Increased enzymeactivity, associationwith?	CHIA	A > G:GA	Asn-Asp	Derived
CM094243	chr1	111656461	+	DFP	Asthma, protectionagainst, associationwith?	CHIA	G > T:TG	Arg-Met	Derived
CM084968	chr1	150552554	-	DP	Psoriasis, increasedrisk, association with	FLG	G > A:AG	Pro-Ser	Derived
CM067657	chr1	156591049	+	DP	Guillain-Barrésyndrome, reducedrisk, association with	CD1E	A > G:GG	Gln-Arg	Ancestral
CM033904	chr1	169444714	+	FP	Flavin-containingmonooxygenase 2(FMO2) gene variant	FMO2	T > C:CC	Term-Gln	Ancestral
CM043273	chr1	195670491	+	DM	Retinitis pigmentosa	CRB1	G > A:AG	Gly-Ser	Derived
CM024366	chr1	224093029	+	DFP	Preeclampsia,association with	EPHX1	A > G:GA	His-Arg	Derived
CM994344	chr10	115795046	+	FP	Gain of function,association with	ADRB1	G > C:CC	Gly-Arg	Ancestral
CM067436	chr11	7020956	+	DM	Spermatogenicfailure	NLRP14	G > A:AG	Ala-Thr	Derived
CM043536	chr11	47326617	-	DM	Cardiomyopathy,hypertrophic?	MYBPC3	T > C:CT	Ser-Gly	Derived
CM035848	chr11	57739196	+	FP	Olfactory receptordeficiency?	OR1S1	G > A:GA	Arg-His	Denisovan
CM087504	chr11	102218830	-	DP	Blood pressure,association with	MMP3	T > C:CC	Lys-Glu	Ancestral
CM041241	chr11	112776038	+	FP	Reduced dopamineD2 receptor(DRD2) receptordensity, associationwith?	ANKK1	G > A:AA	Glu-Lys	Ancestral
CM082943	chr11	118720796	-	DM	Primaryangle-closureglaucoma?	MFRP	C > T:TT	Arg-His	Ancestral
CM075018	chr11	130255852	-	DP	Coronary heartdisease, associationwith	SNX19	A > C:CC	Leu-Arg	Ancestral
CM091988	chr12	32913201	-	DM	Arrhythmogenicright ventricularcardiomyopathy	PKP2	A > G:GG	Leu-Pro	Ancestral
CM087618	chr12	56152088	+	DFP	Inflammatory boweldisease, associationwith	GLI1	G > C:CC	Glu-Gln	Ancestral
CM098354	chr12	120099486	+	FP	Altered function,association with	P2RX7	G > A:AA	Ala-Thr	Ancestral
CM065186	chr13	38162690	+	DP	Colorectal cancer,increased risk,association with	FREM2	T > C:CC	Phe-Ser	Ancestral
CM063919	chr13	45546095	-	FP	Higherthrombin-activatablefibrinolysis inhibitor(TAFI) antigen levels,association with	CPB2	C > T:TT	Ala-Thr	Ancestral
CM044579	chr13	51413355	-	DM	Wilson disease?	ATP7B	A > G:GG	Val-Ala	Ancestral
CM063843	chr14	19994994	+	DFP	Amyotrophic lateralsclerosis, associationwith	APEX1	T > G:GG	Asp-Glu	Ancestral
CM073244	chr14	20010446	+	DP	Faster cognitivedecline inAlzheimer's disease,association with	NP	G > A:AG	Gly-Ser	Derived
CM068495	chr15	49316404	-	DP	Increased corticalbone mass density,association with	CYP19A1	T > C:CC	Val-Val	Ancestral
CM045806	chr15	83248435	+	FP	Reduced affinity forgemcitabine,association with	SLC28A1	G > A:AG	Val-Ile	Derived
CM102885	chr16	10908349	+	DP	Multiple sclerosis,increased risk,association with	CIITA	G > C:CC	Gly-Ala	Ancestral
CM093131	chr16	55950234	+	DP	Helicobacterpylori-related gastriccarcinoma,association with	CCL22	A > C:CC	Asp-Ala	Ancestral
CM067679	chr17	7858004	+	DP	Lung cancer,susceptibility to,association with	GUCY2D	T > A:AA	Leu-His	Ancestral
CM073339	chr17	24310977	-	DM	Febrile seizures?	SEZ6	T > C:CC	Thr-Ala	Ancestral
CM057951	chr17	37960432	+	DP	Endometriosis,association with	HSD17B1	A > G:AG	Ser-Gly	Denisovan
CM994214	chr17	39808591	-	DP	Reduced post-strokemortality, associationwith	ITGA2B	A > C:GC	Ile-Ser	Unsure
CM091892	chr17	42363569	+	DP	Hypertension,association with	GOSR2	G > A:AG	Arg-Lys	Derived
CM091876	chr17	73642170	+	DP	Epidermodysplasiaverruciformis,susceptibility in HIV,association with	TMC8	A > T:TA	Asn-Ile	Derived
CM000831	chr19	3546794	-	DP	Bronchial asthma,association with	TBXA2R	A > G:GG	Tyr-Tyr	Ancestral
CM030470	chr19	18041451	-	DP	Tuberculosis,susceptibility to,association with	IL12RB1	A > G:GG	Met-Thr	Ancestral
CM044082	chr19	18407678	-	DP	Spina bifida, reducedrisk, association with	isyna1	T > C:CC	Leu-Leu	Ancestral
CM057586	chr19	40534926	+	DP	Increased beta-cellfunction, associationwith	FFAR1	G > A:AA	Arg-His	Ancestral
CM057545	chr19	50560149	-	DP	Lung adenocarcinoma,increased risk,association with	ERCC2	G > T:GT	Arg-Arg	Denisovan
CM044227	chr19	60088712	+	DP	Aggressiveperiodontitis,reduced risk, assocwith	FCAR	A > G:GG	Arg-Arg	Ancestral
CM003809	chr2	38155681	-	DP	Breast or lungcancer, associationwith	CYP1B1	C > A:AA	Ala-Ser	Ancestral
CM101950	chr2	98363138	+	DM	Progressive conedystrophy?	CNGA3	C > T:TC	Pro-Leu	Derived
CM092797	chr2	169550992	-	FP	Alternate splicing,association with	ABCB11	T > C:CT	Gly-Gly	Derived
CM066575	chr2	218738088	-	DP	AIDS progression,protection,association with	IL8RA	A > C:CC	Met-Arg	Ancestral
CM057769	chr2	234266408	+	FP	Altered enzymeactivity, associationwith	UGT1A6	T > G:GG	Ser-Ala	Ancestral
CM910018	chr2	241466189	+	DP	Hyperoxaluria,association with	AGXT	A > G:GG	Ile-Met	Ancestral
CM053304	chr20	54257212	+	DP	Obesity, associationwith	MC3R	C > A:AA	Thr-Lys	Ancestral
CM970391	chr22	18331207	+	DFP	Schizoaffectivedisorder, associationwith	COMT	C > G:GG	Leu-Leu	Ancestral
CM961335	chr22	30817700	+	DM	Glucose/galactosemalabsorption	SLC5A1	G > A:AA	Ala-Thr	Ancestral
CM930187	chr22	40853887	-	DP	Parkinson's disease,association with	CYP2D6	G > A:GA	Arg-Cys	Denisovan
CM099899	chr22	41888870	+	FP	Increasedpregnenolone levels,association with	TSPO	A > G:GG	Thr-Ala	Ancestral
CM025430	chr4	2975841	+	FP	Activity, associationwith	GRK4	C > T:TT	Ala-Val	Ancestral
CM013959	chr4	23424760	-	DP	Diabetes, type 2,association with	PPARGC1A	C > T:TC	Gly-Ser	Derived
CM033593	chr4	100479812	-	DP	Alcoholism,increased risk,association with?	ADH1C	T > C:CC	Ile-Val	Ancestral
CM064956	chr4	109893565	-	DP	Colorectal cancer,increased risk,association with	AGXT2L1	A > G:GG	Ser-Pro	Ancestral
CM030066	chr4	149576925	-	FP	Reduced expression,association with	NR3C2	T > C:TC	Ile-Val	Denisovan
CM080365	chr4	155711209	+	DP	Increased clotstiffness, associationwith	FGB	G > A:AA	Arg-Lys	Ancestral
CM057405	chr4	156355126	+	DP	Severe obesity, inmen, associationwith	NPY2R	C > T:TT	Ile-Ile	Ancestral
CM067358	chr5	22114341	-	DP	Lung cancer,susceptibility to,association with	CDH12	C > T:TT	Val-Met	Ancestral
CM094788	chr5	121441107	-	DFP	Breast cancer,increased risk, inAfrican Americanwomen, associationwith	LOX	C > T:TT	Arg-Gln	Ancestral
CM013815	chr5	147461148	+	DP	Atopy, maternallyinherited,association with	SPINK5	G > A:GA	Glu-Lys	Denisovan
CM083577	chr6	24611569	+	DFP	Impaired cognitivefunction, associationwith	ALDH5A1	C > T:TT	His-Tyr	Ancestral
CM086146	chr6	25921129	-	DP	Uric acidconcentration,association with	SLC17A1	G > A:AA	Thr-Ile	Ancestral
CM052232	chr6	80683094	-	DP	Age-relatedmaculopathy,association with	ELOVL4	T > C:CT	Met-Val	Derived
CM073245	chr7	34784638	+	DP	Panic disorder, inmales, associationwith	NPSR1	A > T:TT	Asn-Ile	Ancestral
CM084696	chr7	87017537	-	DFP	Parkinson's disease,association with	ABCB1	A > G:GG	Gly-Gly	Ancestral
CM091200	chr7	129737976	+	DP	Prostate cancer,aggressiveearly-onset,association with	CPA4	G > T:TT	Gly-Cys	Ancestral
CM952203	chr7	142350235	-	FP	Kell blood groupvariation	KEL	A > G:GA	Leu-Pro	Derived
CM073993	chr7	150188598	+	FP	Reduced activity,association with	ABP1	C > G:GG	His-Asp	Ancestral
CM973386	chr8	18124281	+	FP	Increased activity,association with	NAT1	G > A:AG	Val-Ile	Derived
CM099895	chr8	24412708	+	DP	Schizophrenia,association with	ADAM7	A > C:CC	Asn-His	Ancestral
CM064954	chr8	26683945	-	DP	Hypertension,association with?	ADRA1A	A > G:GG	Cys-Arg	Ancestral
CM033767	chr8	27414422	+	DFP	Coronary heartdisease, inCaucasians,association with	EPHX2	A > G:GA	Lys-Arg	Derived
CM034886	chr8	91059655	-	DP	Lung cancer,association with?	NBN	C > G:GG	Glu-Gln	Ancestral
CM045665	chr8	120033233	-	DP	Osteoporoticfractures, associationwith	TNFRSF11B	G > C:CG	Asn-Lys	Derived
CM093465	chr9	2181309	+	DFP	Schizophrenia,association with	SMARCA2	C > G:GC	Asp-Glu	Derived
CM073190	chrX	43475980	+	DP	Bipolar disorder,association with?	MAOA	T > G:TG	Arg-Arg	Denisovan
CR072321	chr1	11841858	-	DFP	Diabetes, type, 2,reduced risk,association with	NPPB	A > G:GG		Ancestral
CR080762	chr1	15645754	+	DM	Pancreatitis, chronic?	CTRC	T > C:CC		Ancestral
CR080761	chr1	15645757	+	DM	Pancreatitis, chronic?	CTRC	A > G:GG		Ancestral
CR016187	chr1	87101113	-	FP	Increasedselenocysteineinsertion sequence(SECIS) efficiency,association with	sep15	C > T:TT		Ancestral
CR092707	chr1	201194130	-	DFP	Lower insulinresistance,association with	ADIPOR1	C > T:TT		Ancestral
CR034628	chr10	26545502	+	DP	Obesity, associationwith?	GAD2	G > A:GA		Denisovan
CR061340	chr11	35397552	-	DFP	Progressing stroke,increased risk,association with	SLC1A2	T > G:GG		Ancestral
CR068212	chr11	59612604	+	DFP	Asthma,aspirin-intolerant	MS4A2	T > C:CC		Ancestral
CR063407	chr14	50069895	-	DP	Diabetes, type 2,reduced risk,association with	MAP4K5	G > A:AA		Ancestral
CR077666	chr15	71712835	-	DFP	Schizophrenia,reduced risk,association with?	NPTN	C > A:CA		Denisovan
CR084880	chr17	35697157	+	DFP	Hepatocellularcarcinoma, reducedrisk, association with	CDC6	A > G:GG		Ancestral
CR087465	chr17	39785770	+	DFP	Frontotemporaldementia,association with	GRN	C > T:TT		Ancestral
CR035036	chr18	647685	+	FP	Transcriptionalactivity, associationwith	TYMS	G > C:CC		Ancestral
CR032436	chr18	45342041	+	DP	High-densitylipoprotein (HDL)cholesterol levels,association with?	LIPG	A > C:CA		Derived
CR087182	chr19	44589133	+	DFP	Rheumatoidarthritis, shorterduration, associationwith	ZFP36	A > G:GG		Ancestral
CR035033	chr19	46188301	+	FP	Cytochrome P-450(CYP) 2B6expression,association with?	CYP2B6	T > C:CC		Ancestral
CR068525	chr2	69467665	-	DFP	Diabetes, type 2,association with	GFPT1	A > G:GG		Ancestral
CR077669	chr2	85748849	-	FP	Increased promoteractivity, associationwith	SFTPB	T > G:GG		Ancestral
CR093507	chr2	168743982	-	DFP	Hypertension,association with	STK39	A > G:GG		Ancestral
CR093026	chr2	169465787	+	DFP	Increased insulinsecretion,association with	G6PC2	G > A:AA		Ancestral
CR073559	chr2	224174588	-	DFP	Hypertension,association with	SCG2	C > T:TT		Ancestral
CR053505	chr20	4653756	+	DP	Creutzfeldt-Jakobdisease, associationwith?	PRND	T > C:CC		Ancestral
CR015272	chr22	40858326	-	FP	Intermediatemetaboliser,association with?	CYP2D6	C > G:GG		Ancestral
CR055620	chr4	75938792	-	FP	Promoter activity,association with	BTC	C > G:GG		Ancestral
CR093469	chr6	2945302	+	DFP	Breast cancer,decreased risk,association with	NQO2	A > C:CA		Derived
CR035882	chr6	78230101	-	DFP	Suicidal ideation, inmajor depression,association with	HTR1B	A > C:CA		Derived
CR025333	chr6	137582213	-	DFP	Malaria,susceptibility,association with	IFNGR1	A > G:GG		Ancestral
CR093919	chr6	153121754	+	DP	Pulmonary arterialhypertension,idiopathic,association with?	VIP	T > C:CC		Ancestral
CR016149	chr7	22732746	+	FP	Alteredtranscriptionalactivity, associationwith	IL6	A > G:GG		Ancestral
CR053504	chr7	91995822	-	FP	Gene expression,association with	PEX1	A > G:GA		Derived
CR041138	chr7	99192235	-	DP	Prostate cancer, lowaggressiveness,association with	CYP3A4	G > A:AG		Derived
CR072316	chr7	128376663	+	FP	Shorter transcript,association with	IRF5	G > A:AA		Ancestral
CR962526	chr8	41774321	-	DM	Spherocytosis	ANK1	A > G:GA		Derived
CR098013	chr9	22109195	+	DFP	Coronary arterydisease, associationwith	CDKN2BAS	C > T:CT		Denisovan
CR044772	chr9	99499399	-	DP	Lung adenocarcinoma,risk, association with	XPA	T > C:CC		Ancestral
CR020828	chr9	106730356	-	DP	Reduced risk ofcoronary arterydisease, associationwith	ABCA1	G > C:CC		Ancestral
CR052068	chr9	136911887	+	FP	Promoter activity,association with	FCN2	A > G:GG		Ancestral
CR042847	chr9	138995962	+	DP	HDL cholesterol,association with?	PTGDS	A > C:CC		Ancestral

Human variants with significantly different population frequencies at sites of PCMs

The FST was used to quantify the allele frequency differences for the different polymorphic PCMs between extant African, Asian and European populations. Alleles that have been the target of localised positive selection tend to exhibit unusually high FST values [22,23]. We therefore compared the FST values of the ancestral polymorphic PCMs with the empirical FST distribution derived from all HapMap SNPs (International HapMap Consortium, 2007),[24] to assess the significance of individual FST values. We identified six PCMs with significantly elevated FST values (Table 5).

Table 5

PCMs (disease-causing and disease-related) with significantly different genotype frequencies in different HapMap populations

					Asian		European		African		Pair-wise FST (p value)
Gene	rs	HGMDAcc	WT	PCM	fWT	n	fWT	n	fWT	n	Asian-African	European-African	Asian-European
SLC24A5	rs1426654	CM054862	A	G	0.01	178	1.00	116	0.03	120	-0.001 (0.8490)	0.974 (0.0054)	0.987 (0.0010)
TP53BP1*	rs2602141	CM067476	T	G	0.52	176	0.69	120	0.00	120	0.470 (0.2830)	0.689 (0.0489)	0.054 (0.5701)
CAPN3*	rs1801449	CM099258	G	A	0.91	178	0.94	120	0.23	120	0.653 (0.2234)	0.143 (0.3877)	0.680 (0.0026)
TP53BP1*	rs560191	CM067475	G	C	0.52	178	0.69	120	0.00	120	0.475 (0.2981)	0.689 (0.0489)	0.051 (0.5536)
ADH1B	rs1229984	CM890003	T	C	0.75	178	0.00	120	0.00	118	0.715 (0.1576)	NA (NA)	0.717 (0.0197)
ENPP1*	rs1044498	CM993455	A	C	0.94	180	0.87	118	0.00	120	0.927 (0.0314)	0.873 (0.0110)	0.020 (0.6004)

*Previously reported by Zhang et al.[10]

rs: reference number, dbSNP, WT: wild type, fWT: frequency of the wild-type allele, NA: Not applicable.

Although four of these PCMs had already been identified in our previous comparative analysis of the human, chimpanzee and Neanderthal genomes,[10] two novel PCMs were identified in the putative cation exchanger SLC24A5 (DP) gene and in the alcohol dehydrogenase ADH1B (FP) gene. These genes have in common the GO terms GO:0046872, GO:0043169 and GO:0043167, terms which relate to metal ion binding, cation binding and ion binding, respectively. The SLC24A5 variant appears to be associated with increased skin pigmentation and predominates in African/East Asian populations [25,26].

In conclusion, using the newly reported genome sequence from a Denisovan hominin, we have identified a number of PCMs in the chimpanzee, Neanderthal and Denisovan. Those human PCMs that were ancestral (ie both the Denisovan nucleotide and the chimpanzee nucleotide were identical to the human DM/disease-associated mutation) could potentially be indicative of either the human lineage-specific loss of compensatory nucleotide changes within the respective genes carrying the PCM, or adaptive differences between modern humans and Denisovans.